vs
Home Federal Bancorp, Inc. of Louisiana（HFBL）与Protalix BioTherapeutics, Inc.（PLX）财务数据对比。点击上方公司名可切换其他公司
Protalix BioTherapeutics, Inc.的季度营收约是Home Federal Bancorp, Inc. of Louisiana的1.5倍（$9.1M vs $6.0M），Home Federal Bancorp, Inc. of Louisiana净利率更高（27.8% vs -60.3%，领先88.2%），Home Federal Bancorp, Inc. of Louisiana同比增速更快（18.2% vs -49.9%），过去两年Home Federal Bancorp, Inc. of Louisiana的营收复合增速更高（10.7% vs -6.7%）
路易斯安那州家联邦银行股份有限公司是美国的银行控股企业，通过旗下子公司开展社区银行业务，为零售客户与本地小型企业提供存款、消费贷款、住房抵押贷款、商业融资等金融服务，服务范围覆盖路易斯安那州各地社区。
Protalix BioTherapeutics是一家以色列制药企业，核心产品为植物源酶制剂他利苷酶阿尔法，该产品已获美国食品药品监督管理局批准，用于治疗戈谢病，专注于开发创新生物技术药物服务患者需求。
HFBL vs PLX — 直观对比
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $6.0M | $9.1M |
| 净利润 | $1.7M | $-5.5M |
| 毛利率 | — | 49.4% |
| 营业利润率 | 35.1% | -51.1% |
| 净利率 | 27.8% | -60.3% |
| 营收同比 | 18.2% | -49.9% |
| 净利润同比 | 64.2% | -184.8% |
| 每股收益（稀释后） | $0.54 | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $6.0M | $9.1M | ||
| Q3 25 | $5.9M | $17.9M | ||
| Q2 25 | $5.6M | $15.7M | ||
| Q1 25 | $5.2M | $10.1M | ||
| Q4 24 | $5.1M | $18.2M | ||
| Q3 24 | $4.7M | $18.0M | ||
| Q2 24 | $4.9M | $13.5M | ||
| Q1 24 | $4.9M | — |
| Q4 25 | $1.7M | $-5.5M | ||
| Q3 25 | $1.6M | $2.4M | ||
| Q2 25 | $1.2M | $164.0K | ||
| Q1 25 | $748.0K | $-3.6M | ||
| Q4 24 | $1.0M | $6.5M | ||
| Q3 24 | $941.0K | $3.2M | ||
| Q2 24 | $638.0K | $-2.2M | ||
| Q1 24 | $732.0K | — |
| Q4 25 | — | 49.4% | ||
| Q3 25 | — | 53.4% | ||
| Q2 25 | — | 62.5% | ||
| Q1 25 | — | 19.1% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 53.4% | ||
| Q2 24 | — | 29.8% | ||
| Q1 24 | — | — |
| Q4 25 | 35.1% | -51.1% | ||
| Q3 25 | 34.1% | 11.9% | ||
| Q2 25 | 27.5% | 7.5% | ||
| Q1 25 | 18.3% | -41.0% | ||
| Q4 24 | 23.7% | 39.6% | ||
| Q3 24 | 19.9% | 22.2% | ||
| Q2 24 | 16.9% | -18.0% | ||
| Q1 24 | 18.5% | — |
| Q4 25 | 27.8% | -60.3% | ||
| Q3 25 | 27.1% | 13.2% | ||
| Q2 25 | 20.9% | 1.0% | ||
| Q1 25 | 14.4% | -35.8% | ||
| Q4 24 | 20.0% | 35.6% | ||
| Q3 24 | 19.9% | 18.0% | ||
| Q2 24 | 13.1% | -16.4% | ||
| Q1 24 | 14.9% | — |
| Q4 25 | $0.54 | $-0.06 | ||
| Q3 25 | $0.52 | $0.03 | ||
| Q2 25 | $0.38 | $0.00 | ||
| Q1 25 | $0.24 | $-0.05 | ||
| Q4 24 | $0.33 | $0.10 | ||
| Q3 24 | $0.31 | $0.03 | ||
| Q2 24 | $0.21 | $-0.03 | ||
| Q1 24 | $0.24 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $14.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $57.7M | $48.2M |
| 总资产 | $621.4M | $82.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | — | $14.7M | ||
| Q3 25 | — | $13.6M | ||
| Q2 25 | — | $17.9M | ||
| Q1 25 | — | $19.5M | ||
| Q4 24 | — | $19.8M | ||
| Q3 24 | — | $27.4M | ||
| Q2 24 | — | $23.4M | ||
| Q1 24 | — | — |
| Q4 25 | $57.7M | $48.2M | ||
| Q3 25 | $56.6M | $52.9M | ||
| Q2 25 | $55.2M | $49.9M | ||
| Q1 25 | $54.7M | $45.2M | ||
| Q4 24 | $53.9M | $43.2M | ||
| Q3 24 | $54.3M | $32.4M | ||
| Q2 24 | $52.8M | $28.6M | ||
| Q1 24 | $52.5M | — |
| Q4 25 | $621.4M | $82.3M | ||
| Q3 25 | $622.6M | $82.3M | ||
| Q2 25 | $609.5M | $78.5M | ||
| Q1 25 | $619.6M | $73.9M | ||
| Q4 24 | $607.8M | $73.4M | ||
| Q3 24 | $628.4M | $61.6M | ||
| Q2 24 | $637.5M | $91.5M | ||
| Q1 24 | $643.0M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $2.9M | $2.0M |
| 自由现金流经营现金流 - 资本支出 | — | $1.6M |
| 自由现金流率自由现金流/营收 | — | 17.8% |
| 资本支出强度资本支出/营收 | — | 4.4% |
| 现金转化率经营现金流/净利润 | 1.70× | — |
| 过去12个月自由现金流最近4个季度 | — | $-13.6M |
8季度趋势，按日历期对齐
| Q4 25 | $2.9M | $2.0M | ||
| Q3 25 | $2.8M | $-3.7M | ||
| Q2 25 | $5.5M | $-5.2M | ||
| Q1 25 | $991.0K | $-5.1M | ||
| Q4 24 | $2.6M | $4.0M | ||
| Q3 24 | $871.0K | $4.1M | ||
| Q2 24 | $2.3M | $-3.6M | ||
| Q1 24 | $650.0K | — |
| Q4 25 | — | $1.6M | ||
| Q3 25 | — | $-4.2M | ||
| Q2 25 | — | $-5.7M | ||
| Q1 25 | — | $-5.4M | ||
| Q4 24 | — | $3.6M | ||
| Q3 24 | $843.0K | $4.0M | ||
| Q2 24 | $2.3M | $-3.8M | ||
| Q1 24 | — | — |
| Q4 25 | — | 17.8% | ||
| Q3 25 | — | -23.7% | ||
| Q2 25 | — | -36.2% | ||
| Q1 25 | — | -53.0% | ||
| Q4 24 | — | 19.6% | ||
| Q3 24 | 17.8% | 22.4% | ||
| Q2 24 | 46.8% | -28.1% | ||
| Q1 24 | — | — |
| Q4 25 | — | 4.4% | ||
| Q3 25 | — | 2.8% | ||
| Q2 25 | — | 2.8% | ||
| Q1 25 | — | 3.0% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | 0.6% | 0.5% | ||
| Q2 24 | 0.8% | 1.3% | ||
| Q1 24 | — | — |
| Q4 25 | 1.70× | — | ||
| Q3 25 | 1.74× | -1.58× | ||
| Q2 25 | 4.64× | -31.91× | ||
| Q1 25 | 1.32× | — | ||
| Q4 24 | 2.54× | 0.61× | ||
| Q3 24 | 0.93× | 1.27× | ||
| Q2 24 | 3.63× | — | ||
| Q1 24 | 0.89× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HFBL
暂无分部数据
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
